New Gout Therapies Show Promise in Phase III Trials At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0

Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D

• Upadacitinib is a Double Edged Vascular Sword in GCA | RheumNow

NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X Finally good news in Sjogrens disease. @RheumNow #ACR25

• NEPTUNUS: Ianalumab in Sjogren's

CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo Premeds immune suppression What to use, ?if anything Cons Is it safe ?long term effectiveness What is failure rate ICANs and other side effects #ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP

• https://x.com/Janetbirdope/status/1983902022501081162/photo/1
• https://x.com/Janetbirdope/status/1983902022501081162/photo/1
• https://twitter.com/Janetbirdope/status/1983901002677023202

LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN: 🔹100% discontinued biologics & IS at follow-up 🔹Renal response ~78% 🔹CRS mostly Grade 1–2 (~70%); ≥Grade 3 AEs = transient & hematologic @RheumNow #ACR25 https://t.co/oNK4wtLGYV

• https://x.com/AkhilSoodMD/status/1983713052618080271/photo/1
• https://x.com/AkhilSoodMD/status/1983713052618080271/photo/1

What to use in future for active #Sjogren's #SjD B cell depletion, signal attenuation Ianalumab 2+ phase3 RCTs Telitacept +RCT Nipocalimab FcRn +Ph2 Dazodalibep CD40L +Ph2 +RCTs HCQ+Lef Rituximab ?BTKi #ACR25 @ACRheum @RheumNow abst#LB24, LB11

#MTX is NOT the same as TCZ in #GCA in RCT #TCZ did better So use an advanced Rx for GCA ex TCZ, Upa when approved METOGiA RCT - more relapses in MTX abst#891 #ACR25 @ACRheum @RheumNow https://t.co/wsEKGF8dW2

• https://x.com/Janetbirdope/status/1983654734646108174/photo/1

#GCA & #PMR @ACRheum #ACR25 #gamechangers #ACRBest Yr 2 Select-GCA abst#776 #upadacitinib in yr2 of GCA REDUCES flares HELPFUL info ?ability to get drug for 2 yrs hopefully Failed Phase3 RCT of #secukinumab in #GCA helped #PMR abst#1175 & +Ph3 for PMR REPLENISH RCT @RheumNow https://t.co/5lH6HXhnfg

• https://x.com/Janetbirdope/status/1983651705385636208/photo/1
• https://x.com/Janetbirdope/status/1983651705385636208/photo/1

Next Generation T-Cell Engager: The Future Dr. Alfred Kim reviews abstract 0001 presented at #ACR25. https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l

• https://buff.ly/zdyA0e1